Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-05, Stock:NVS, The news for the past five days is as follows:
2019-01-29: NEWS1: Pre-Market Earnings Report for January 30, 2019 :  T, BABA, BA, MCD, TMO, ANTM, ADP, GD, NVS, SIRI, RCL, IR.NEWS2: Pre-Market Earnings Report for January 30, 2019 :  T, BABA, BA, MCD, TMO, ANTM, ADP, GD, NVS, SIRI, RCL, IR.NEWS3: Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid.NEWS4: Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid.NEWS5: Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid.
2019-01-30: NEWS1: Novartis Slides On Earnings Lag, But Sees 10 New Blockbusters By 2020.NEWS2: Despite Raising Prices, Big Pharma Is Selling Drugs for Less.NEWS3: McDonald’s posts earnings, Boeing has huge quarter, Novartis has a new plan.NEWS4: McDonald’s posts earnings, Boeing has historical quarter, Novartis has a new plan.NEWS5: Novartis CEO sees 'further conversation' on Sandoz future in 18 months.NEWS6: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for January 31, 2019.NEWS7: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for January 31, 2019.NEWS8: A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype.NEWS9: A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype.NEWS10: Novartis Dips After Drug Giant Lags Fourth-Quarter Expectations.NEWS11: Novartis 2019 growth outlook leaves investors wanting more.NEWS12: The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance.NEWS13: A Cure for Cancer Next Year? The Stock Market Says Don&apos;t Believe the Hype.NEWS14: Novartis Misses Earnings and Sales Estimates in Q4.NEWS15: Novartis Misses Earnings and Sales Estimates in Q4.NEWS16: Earnings Reaction History: Novartis AG, 70.0% Follow-Through Indicator, 2.4% Sensitive.NEWS17: Earnings Reaction History: Novartis AG, 70.0% Follow-Through Indicator, 2.4% Sensitive.NEWS18: Novartis: 4Q Earnings Snapshot.NEWS19: Novartis Seeks Growth in Newer Drugs Amid Pricing Challenges.NEWS20: Novartis Misses Earnings and Sales Estimates in Q4.NEWS21: [$$] Novartis's Bet on Higher-Value Drugs Pays Off.NEWS22: [$$] Novartis forecasts mid-single digit sales growth in 2019.NEWS23: [$$] Novartis Sales Boosted by Oncology.NEWS24: Novartis earnings narrowly miss expectations, shares down 2%.NEWS25: Novartis earnings narrowly miss expectations, shares down 2%.NEWS26: Novartis Stock Dips As Q4 Profit Misses View; Plans Buyback; Sees Growth In FY19.NEWS27: Novartis Stock Dips As Q4 Profit Misses View; Plans Buyback; Sees Growth In FY19.NEWS28: Novartis Q4 Core Earnings Miss Estimates; Sees Growth In FY19.NEWS29: Novartis Q4 Core Earnings Miss Estimates; Sees Growth In FY19.
2019-01-31: NEWS1: Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y.NEWS2: Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y.NEWS3: Novartis Posts Earnings, Revenue Miss.NEWS4: Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y.NEWS5: Why are deep-pocketed biotechs cutting hundreds of jobs?.
2019-02-01: NEWS1: Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance.NEWS2: Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance.NEWS3: Mylan's Generic Version of Advair Diskus Wins FDA Approval.NEWS4: Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance.NEWS5: Gene Therapy: Novartis Under The Microscope With Novel Treatment.NEWS6: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS7: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS8: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.
2019-02-04: NEWS1: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS2: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS3: What's in the Cards for Glaxo (GSK) This Earnings Season?.NEWS4: What's in the Cards for Glaxo (GSK) This Earnings Season?.NEWS5: Better Buy: Johnson & Johnson vs. Merck & Co..NEWS6: Better Buy: Johnson & Johnson vs. Merck & Co..NEWS7: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS8: What's in the Cards for Glaxo (GSK) This Earnings Season?.NEWS9: [$$] Novartis Backs Lutathera Pricing After Price-Gouging Accusations.

Answer: Rise